Future Vaccine Development at NICHD
- 1 December 2004
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1038 (1) , 49-59
- https://doi.org/10.1196/annals.1315.011
Abstract
Using published data and the results of our studies, we hypothesized that a critical level of serum IgG antibodies to the surface structures of invasive pathogens (capsular polysaccharides of Haemophilus influenzae type b, pneumococcus, meningococcus, Salmonella typhi, Escherichia coli, and Staphylococcus aureus, the O-specific polysaccharide LPS domain of the LPS of Shigella, non-typhoidal Salmonella, and E. coli, and the capsular polypeptide of Bacillus anthraces) confer immunity to these pathogens. Covalent attachment to a protein increases their immunogenicity and bestows T-cell properties to these antigens. We have also shown that a critical level of serum IgG antibodies to pertussis toxin alone induces immunity on both an individual and on a community basis (herd immunity) to Bordetella pertussis. It is likely that all the above conjugates and pertussis toxoid will be incorporated into vaccines for routine infant immunization.Keywords
This publication has 73 references indexed in Scilit:
- Persistent Efficacy of Vi Conjugate Vaccine against Typhoid Fever in Young ChildrenNew England Journal of Medicine, 2003
- Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracisJournal of Industrial Microbiology & Biotechnology, 2002
- Use of aStaphylococcus aureusConjugate Vaccine in Patients Receiving HemodialysisNew England Journal of Medicine, 2002
- The Efficacy of aSalmonella typhiVi Conjugate Vaccine in Two-to-Five-Year-Old ChildrenNew England Journal of Medicine, 2001
- Clostridium difficile Recombinant Toxin A Repeating Units as a Carrier Protein for Conjugate Vaccines: Studies of Pneumococcal Type 14, Escherichia coli K1, and Shigella flexneri Type 2a Polysaccharides in MiceInfection and Immunity, 2000
- SERUM ANTIBODIES IN SIX-YEAR-OLD CHILDREN VACCINATED IN INFANCY WITH A HAEMOPHILUS INFLUENZAE TYPE b-TETANUS TOXOID CONJUGATE VACCINEThe Pediatric Infectious Disease Journal, 1996
- Clinical and immunologic responses to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants injected at 3, 5, 7, and 18 months of ageThe Journal of Pediatrics, 1991
- Duration of serum antibodies elicited by Haemophilus influenzae type b capsular polysaccharide alone or conjugated to tetanus toxoid in 18- to 23-month-old childrenThe Journal of Pediatrics, 1990
- Prevention of Typhoid Fever in Nepal with the VI Capsular Polysaccharide ofSalmonella TyphiNew England Journal of Medicine, 1987
- The attack rate, age incidence, racial distribution, and case fatality rate of Hemophilus influenzae type b meningitis in Mecklenburg County, North CarolinaThe Journal of Pediatrics, 1972